Wiid Zirke, Liang Caihua, Bruyndonckx Robin, Mason Lauren, Polkowska-Kramek Aleksandra, Peerawaranun Pimnara, Esnaola Mikel, Ewnetu Worku Biyadgie, Basu Somsuvro, Witcombe David, Gessner Bradford D, Begier Elizabeth
Pfizer Australia, Sydney, Australia.
Pfizer Inc., New York City, USA.
Influenza Other Respir Viruses. 2025 Apr;19(4):e70092. doi: 10.1111/irv.70092.
Respiratory syncytial virus (RSV) morbidity and mortality in adults are often underestimated due to nonspecific symptoms, limited standard-of-care testing and lower diagnostic testing sensitivity compared with children. To accurately evaluate the RSV disease burden among adults in Australia, we conducted a model-based study to estimate RSV-attributable cardiorespiratory hospitalisation incidence and mortality rate.
A quasi-Poisson regression model was used to estimate RSV-attributable cardiorespiratory, respiratory and cardiovascular events, using weekly hospitalisation and mortality data from 2010 to 2019, accounting for periodic and aperiodic time trends and viral activity and allowing for potential overdispersion. The time-series model compared the variability in confirmed RSV events alongside variability in all-cause cardiorespiratory events identified from ICD-10-AM codes to estimate the number of RSV-attributable events, including undiagnosed RSV-related events.
RSV-attributable incidence of cardiorespiratory hospitalisations increased with age and was highest among adults ≥ 65 years (329.5-386.6 cases per 100,000 person-years), nine times higher than in adults 18-64 years. The estimated incidence of RSV-attributable respiratory hospitalisations in adults ≥65 years (219.7-247.8 cases per 100,000 person-years) was 35-fold higher than in adults 18-64 years. RSV-attributable deaths accounted for 4% to 6% of cardiorespiratory deaths in adults ≥ 65 years, with RSV-attributable mortality rates ranging from 65.6 to 77.6 deaths per 100,000 person-years and respiratory mortality rates ranging from 20.3 to 24.0 deaths per 100,000 person-years, both 70-fold higher than in adults 18-64 years.
This study identified substantial RSV-associated morbidity and mortality among Australian adults and is the first study to report RSV-attributable mortality rates for Australia that account for untested events.
由于症状不具特异性、标准护理检测有限以及与儿童相比诊断检测敏感性较低,成人呼吸道合胞病毒(RSV)的发病率和死亡率常常被低估。为准确评估澳大利亚成人中RSV疾病负担,我们开展了一项基于模型的研究,以估算RSV所致心肺住院发病率和死亡率。
采用准泊松回归模型,利用2010年至2019年的每周住院和死亡率数据估算RSV所致心肺、呼吸和心血管事件,考虑周期性和非周期性时间趋势以及病毒活性,并允许潜在的过度离散。时间序列模型比较确诊的RSV事件的变异性与从ICD-10-AM编码确定的全因心肺事件的变异性,以估算RSV所致事件的数量,包括未确诊的RSV相关事件。
RSV所致心肺住院发病率随年龄增长而增加,在≥65岁的成年人中最高(每10万人年329.5 - 386.6例),比18 - 64岁的成年人高9倍。≥65岁成年人中RSV所致呼吸住院的估计发病率(每10万人年219.7 - 247.8例)比18 - 64岁的成年人高35倍。RSV所致死亡占≥65岁成年人心肺死亡的4%至6%,RSV所致死亡率为每10万人年65.6至77.6例死亡,呼吸死亡率为每10万人年20.3至24.0例死亡,两者均比18 - 64岁的成年人高70倍。
本研究确定了澳大利亚成人中与RSV相关的大量发病和死亡情况,并且是第一项报告澳大利亚RSV所致死亡率且考虑了未检测事件的研究。